The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease
Open accessAbstract
Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and viral pneumonia in infants and young children. Administration of a formalin inactivated vaccine against RSV to children in the 1960s resulted in increased morbidity and mortality in vaccine recipients who subsequently contracted RSV. This incident precluded development of subunit RSV vaccines for infants for over 30 years, because the mechanism of illness was never clarified. An RSV vaccine for infants is still not available. Here, we demonstrate that enhanced RSV disease is mediated by immune complexes and abrogated in complement component C3 and B cell–deficient mice but not in controls. Further, we show correlation with the enhanced disease observed in children by providing evidence of complement activation in postmortem lung sections from children with enhanced RSV disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-13: Central Mediator of Allergic Asthma
Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T. Y., Karp, C. L., & Donaldson, D. D. (1998) · Science · doi:10.1126/science.282.5397.2258 · Cited by 2,617
Self-citationKIM, H. W., CANCHOLA, J. G., BRANDT, C. D., PYLES, G., CHANOCK, R. M., JENSEN, K., & PARROTT, R. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120955 · Cited by 1,981
Groothuis, J. R., Simoes, E., Levin, M. J., Hall, C. B., Long, C. E., Rodriguez, W. J., Arrobio, J., Meissner, H. C., Fulton, D. R., Welliver, R. C., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311183292102 · Cited by 744
Self-citationGraham, B. S., Henderson, G. S., Tang, Y. W., Lu, X., Neuzil, K. M., & Colley, D. G. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.4.2032 · Cited by 396
Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma
Karp, C. L., Grupe, A., Schadt, E., Ewart, S. L., Keane-Moore, M., Cuomo, P. J., Köhl, J., Wahl, L., Kuperman, D., Germer, S., et al. (2000) · Nature Immunology · doi:10.1038/79759 · Cited by 378
Self-citationA role for the C3a anaphylatoxin receptor in the effector phase of asthma
Humbles, A. A., Lu, B., Nilsson, C. A., Lilly, C., Israel, E., Fujiwara, Y., Gerard, N. P., & Gerard, C. (2000) · Nature · doi:10.1038/35023175 · Cited by 353
Connors, M., Giese, N. A., Kulkarni, A. B., Firestone, C. Y., Morse, H. C., & Murphy, B. R. (1994) · Journal of Virology · doi:10.1128/jvi.68.8.5321-5325.1994 · Cited by 348
Prince, G. A., Jenson, A. B., Hemming, V. G., Murphy, B. R., Walsh, E. E., Horswood, R. L., & Chanock, R. M. (1986) · Journal of Virology · doi:10.1128/jvi.57.3.721-728.1986 · Cited by 309
Self-citationNeutrophil Recruitment by Tumor Necrosis Factor from Mast Cells in Immune Complex Peritonitis
Zhang, Y., Ramos, B. F., & Jakschik, B. A. (1992) · Science · doi:10.1126/science.1470922 · Cited by 284
Srikiatkhachorn, A., & Braciale, T. J. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.3.421 · Cited by 280
Cited by
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Rapid COVID-19 vaccine development
Graham, B. S. (2020) · Science · doi:10.1126/science.abb8923 · Cited by 771
Inhibition of respiratory viruses by nasally administered siRNA
Bitko, V., Musiyenko, A., Shulyayeva, O., & Barik, S. (2005) · Nature Medicine · doi:10.1038/nm1164 · Cited by 725
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Lee, W. S., Wheatley, A. K., Kent, S. J., & DeKosky, B. J. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00789-5 · Cited by 676
Respiratory Syncytial Virus—A Comprehensive Review
Borchers, A. T., Chang, C., Gershwin, M. E., & Gershwin, L. J. (2013) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-013-8368-9 · Cited by 645
The role of IgG Fc receptors in antibody-dependent enhancement
Bournazos, S., Gupta, A., & Ravetch, J. V. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00410-0 · Cited by 617
Tseng, C.-T., Sbrana, E., Iwata-Yoshikawa, N., Newman, P. C., Garron, T., Atmar, R. L., Peters, C. J., & Couch, R. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035421 · Cited by 561
Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.043 · Cited by 532
“This metric has been identified as a potentially important indicator of vaccine safety, as high levels of binding yet nonneutralizing or weakly neutralizing Abs may contribute to vaccine-associated enhancement of respiratory disease (Graham, 2020; Kim et al., 1969; Polack et al., 2002).”
Delgado, M. F., Coviello, S., Monsalvo, A. C., Melendi, G. A., Hernandez, J. Z., Batalle, J. P., Diaz, L., Trento, A., Chang, H.-Y., Mitzner, W., et al. (2009) · Nature Medicine · doi:10.1038/nm.1894 · Cited by 500
Self-citationViral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis
Collins, P. L., & Graham, B. S. (2008) · Journal of Virology · doi:10.1128/jvi.01625-07 · Cited by 486
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
Arvin, A. M., Fink, K., Schmid, M. A., Cathcart, A., Spreafico, R., Havenar-Daughton, C., Lanzavecchia, A., Corti, D., & Virgin, H. W. (2020) · Nature · doi:10.1038/s41586-020-2538-8 · Cited by 485
Respiratory syncytial virus entry and how to block it
Battles, M. B., & McLellan, J. S. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0149-x · Cited by 402
Respiratory Syncytial Virus: Virology, Reverse Genetics, and Pathogenesis of Disease
Collins, P. L., Fearns, R., & Graham, B. S. (2013) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-38919-1_1 · Cited by 380
Khurana, S., Verma, N., Yewdell, J. W., Hilbert, A. K., Castellino, F., Lattanzi, M., Del Giudice, G., Rappuoli, R., & Golding, H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002336 · Cited by 356
Viral Load Drives Disease in Humans Experimentally Infected with Respiratory Syncytial Virus
DeVincenzo, J. P., Wilkinson, T., Vaishnaw, A., Cehelsky, J., Meyers, R., Nochur, S., Harrison, L., Meeking, P., Mann, A., Moane, E., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201002-0221oc · Cited by 330
Lajoie, S., Lewkowich, I. P., Suzuki, Y., Clark, J. R., Sproles, A. A., Dienger, K., Budelsky, A. L., & Wills-Karp, M. (2010) · Nature Immunology · doi:10.1038/ni.1926 · Cited by 329
Self-citationThe Stoichiometry of Antibody-Mediated Neutralization and Enhancement of West Nile Virus Infection
Pierson, T. C., Xu, Q., Nelson, S., Oliphant, T., Nybakken, G. E., Fremont, D. H., & Diamond, M. S. (2007) · Cell Host & Microbe · doi:10.1016/j.chom.2007.03.002 · Cited by 308
Immune Responses and Disease Enhancement during Respiratory Syncytial Virus Infection
Openshaw, P. J. M., & Tregoning, J. S. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.3.541-555.2005 · Cited by 292
Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease
van Erp, E. A., Luytjes, W., Ferwerda, G., & van Kasteren, P. B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00548 · Cited by 281
Bovine respiratory syncytial virus infection
Valarcher, J.-F., & Taylor, G. (2007) · Veterinary Research · doi:10.1051/vetres:2006053 · Cited by 267
Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes
Monsalvo, A. C., Batalle, J. P., Lopez, M. F., Krause, J. C., Klemenc, J., Hernandez, J. Z., Maskin, B., Bugna, J., Rubinstein, C., Aguilar, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2262 · Cited by 262
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Culley, F. J., Pollott, J., & Openshaw, P. J. M. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020943 · Cited by 259
Graham, B. S. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00972.x · Cited by 239
Immunological Lessons from Respiratory Syncytial Virus Vaccine Development
Ruckwardt, T. J., Morabito, K. M., & Graham, B. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.007 · Cited by 185
Tseng, C.-T., Sbrana, E., Iwata-Yoshikawa, N., Newman, P. C., Garron, T., Atmar, R. L., Peters, C. J., & Couch, R. B. (2012) · PLoS ONE · doi:10.1371/annotation/2965cfae-b77d-4014-8b7b-236e01a35492 · Cited by 122
Lambert, P.-H., Ambrosino, D. M., Andersen, S. R., Baric, R. S., Black, S. B., Chen, R. T., Dekker, C. L., Didierlaurent, A. M., Graham, B. S., Martin, S. D., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.05.064 · Cited by 119
Decay of Fc-dependent antibody functions after mild to moderate COVID-19
Lee, W. S., Selva, K. J., Davis, S. K., Wines, B. D., Reynaldi, A., Esterbauer, R., Kelly, H. G., Haycroft, E. R., Tan, H.-X., Juno, J. A., et al. (2020) · doi:10.1101/2020.12.13.20248143 · Cited by 80
Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
Rossey, I., & Saelens, X. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1675520 · Cited by 32
Hennrich, A. A., Sawatsky, B., Santos-Mandujano, R., Banda, D. H., Oberhuber, M., Schopf, A., Pfaffinger, V., Wittwer, K., Riedel, C., Pfaller, C. K., et al. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009064 · Cited by 30
Metadata
- Authors
- Polack, F. P., Teng, M. N., L.Collins, P., Prince, G. A., Exner, M., Regele, H., Lirman, D. D., Rabold, R., Hoffman, S. J., Karp, C. L., Kleeberger, S. R., Wills-Karp, M., & Karron, R. A.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2002-09-09
- Volume
- 196
- Issue
- 6
- Pages
- 859-865
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2134249387
- Cited by
- 400
- References
- 25
- FWCI
- 10.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.